LANSING, MI - October 21, 2013 - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company"), the leading developer of advanced spider silk based fibers, and Warwick Mills, Inc. ("Warwick"), a leader in the engineering and development of advanced technical textiles and other protective materials, jointly announced today that they have signed a collaborative development agreement concerning the development and commercialization of advanced textiles utilizing Kraig's Monster Silk™ recombinant spider silk technology.
Under terms of the agreement, the two companies will jointly develop innovative textile products based on Kraig's Monster Silk™ fibers. Under the terms of the agreement, the two companies will jointly own textile product related intellectual property which is developed as a result of the collaboration.
Joint development will initially focus on Monster Silk™ weaving, testing and near term applications. The companies believe that this collaborative relationship will help expedite the commercialization of Monster Silk™ and future spider silk based technical fibers.
"This collaborative undertaking represents a huge step forward in our commercialization efforts. The pairing of Kraig's spider silk technology with Warwick's world-class technical textiles applications engineering and weaving abilities is a bold move which we believe will enhance and accelerate the penetration of spider silk into technical textile markets," said Kraig CEO and founder, Kim K. Thompson.
"Warwick Mills is recognized for engineering technical textiles with protective applications and its ability to bridge the gaps between innovative technologies and market integration. Their global reputation is built on the foundation of innovation and performance. I believe the joint development agreement is an important milestone and that Warwick's impressive capabilities makes them an ideal bridge builder between Kraig's expertise in spider silk technologies and the capturing of market share in the technical textiles arena," concluded Thompson.
"Warwick is looking forward to developing new textiles in cooperation with Kraig Biocraft Laboratories, and its Monster Silk™ technology. Spider silk fibers are a powerful new technological approach to potentially opening up new application and markets," stated Charles Howland, President of Warwick.
"The future of textiles will continue to be driven by innovation and we believe that our textile engineering capabilities and Kraig's fibers can change the game in some important applications. These technologies could potentially result in higher performance textiles which would enable very advanced safety and military equipment. This collaborative agreement is a big step forward in the development of exciting new textiles with potential applications for the technical textiles and protective textiles marketplace," concluded Howland.
About Warwick Mills
For the past century, Warwick Mills (http://www.warwickmills.com) has been a leader in the engineering of technical textiles for protective applications. Warwick develops and integrates complex fiber composites for the most challenging safety applications. Its cooperative development strategy relies on its core technologies in technical textiles, custom adhesives, and performance coatings, from research and development to testing and full-scale manufacturing. This strategy ensures customer confidence for every challenge.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Hansel Capital, LLC.
SOURCE: Kraig Biocraft Laboratories, Inc.